Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
| Autor: | Andrew Feldman, Np, Restifo, Hr, Alexander, Dl, Bartlett, Hwu P, Seth P, Sk, Libutti |
|---|---|
| Předmět: |
Time Factors
Recombinant Fusion Proteins Mice Nude Angiogenesis Inhibitors Antineoplastic Agents Genetic Therapy Neoplasms Experimental Peptide Fragments Article Adenoviridae Cell Line Endostatins Mice Inbred C57BL Mice Injections Intravenous Tumor Cells Cultured Animals Humans Female Collagen Cell Division |
| Zdroj: | Europe PubMed Central |
| Popis: | Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8–33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a “factory” to produce high circulating levels of antiangiogenic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|